Is Pfizer's 7% dividend yield sustainable?

The dividend yield may be under pressure if revenues continue to decline due to patent expirations on key drugs, making it a potential value trap.

Which stock is better for long-term investors?

Based on the analysis, Abbott may be a better choice due to its diversified product line and stability, while Pfizer requires careful monitoring.

Abbott Labs vs. Pfizer: Which Healthcare Stock Is a Value Trap?

Abbott Laboratories stock has fallen nearly 23% year-to-date, while Pfizer offers a 7% dividend yield. Both beat Q1 estimates, but the question remains: which is a genuine buying opportunity and which is a value trap?

July 13, 2026

2 min read

Source: 24/7 Wall St.

Key Numbers

ABT YTD decline

~23%

PFE dividend yield

Q1 beat

both

According to an analysis by 24/7 Wall St., investors are eyeing discounted healthcare stocks, but not every decline represents a real opportunity.

Rating Change

No official rating change has been issued, but the analysis compares Abbott (ABT) and Pfizer (PFE) based on performance and valuation.

Analyst Rationale

Analysts suggest that Abbott's 23% decline this year may be overdone, especially after its Q1 earnings beat. In contrast, Pfizer's attractive 7% dividend yield could be a value trap if revenue pressures from patent expirations persist.

Context

Abbott: Down 23% YTD but beat Q1 earnings estimates. Pfizer: Offers a 7% yield, but faces headwinds from declining COVID vaccine sales and generic competition.

What to Make of It

Investors should distinguish between temporary dips and structural issues. Abbott may be a better opportunity due to its diversified product base and stability, while Pfizer requires close monitoring to assess dividend sustainability.

Frequently Asked Questions

The decline is mainly due to broad market concerns and slower growth in some healthcare segments, but the company continues to beat earnings estimates.

Found this useful? Share it

This article was rewritten in Wrqti's editorial style based on information from the original source above. Content is informational only — not investment advice.